Hanyang Med Rev.  2012 May;32(2):118-125. 10.7599/hmr.2012.32.2.118.

Target Therapy for Hepatocellular Carcinoma

Affiliations
  • 1Division of Hepatology-Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yoonsk@catholic.ac.kr

Abstract

Hepatocellular carcinoma (HCC) is a highly malignant tumor that has limited treatment options in its advanced state. The efficacy of current anti-cancer chemotherapy in advanced HCC has not been satisfactory, and the management of HCC remains a major challenge for physicians. However, recent advancement in our understanding of the molecular mechanisms underlying carcinogenesis has provided novel targets in key signaling pathways for tumor development. Recently, Sorafenib (Nexavar), a multi-kinase inhibitor targeting membrane receptors involved in angiogenic and mitogenic intra-cellular signaling including Raf, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptors (PDGFR), has been approved worldwide as a new target agent for HCC, and subsequent clinical trials of newly developed molecular target agents such as Brivanib and Everolimus are being conducted globally. In the near future, continued research will lead to the identification of additional molecular targets in HCC and lead to treatments with enhanced efficacy and improved tolerability.

Keyword

Carcinoma, Hepatocellular; Molecular Targeted Therapy; Sorafenib; Signal Transduction

MeSH Terms

Alanine
Carcinoma, Hepatocellular
Membranes
Molecular Targeted Therapy
Niacinamide
Phenylurea Compounds
Receptors, Platelet-Derived Growth Factor
Receptors, Vascular Endothelial Growth Factor
Signal Transduction
Sirolimus
Triazines
Everolimus
Alanine
Niacinamide
Phenylurea Compounds
Receptors, Platelet-Derived Growth Factor
Receptors, Vascular Endothelial Growth Factor
Sirolimus
Triazines
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error